Quest for the right Drug
מרקאין % 0.5 MARCAINE 0.5 % (BUPIVACAINE HYDROCHLORIDE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
אפידורל, לתוך הזנבעצם הזנב, לתוך עצב, לאגן, לעצבי הצלעות, זריקה באזור צוואר הרחם : EPIDURAL, CAUDAL, PUDENTAL, SACRAL, INTERCOSTAL, PARACERVICAL
צורת מינון:
תמיסה להזרקה : SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Undesirable effects caused by the medicinal product itself may be difficult to distinguish from the physiological effects of nerve block (e.g. decrease in blood pressure, bradycardia), cases caused directly by the needle puncture (e.g. nerve damage), or cases caused indirectly by the needle puncture (e.g. epidural abscess). Neurological injury is a rare but well-known consequential adverse effect of regional anaesthesia, particularly in epidural and spinal anaesthesia. For information on the symptoms and treatment of acute systemic toxicity, refer to section 4.9, Overdose. Organ system Frequency Symptoms Immune system Rare (≥1/10,000, <1/1,000) Allergic reactions, anaphylactic shock disorders Central and Common (≥1/100, <1/10) Paraesthesia, dizziness peripheral nervous system disorders Uncommon (≥1/1,000, <1/100) Symptoms of CNS toxicity (convulsions, circumoral paraesthesia, tongue numbness, hyperacousis, vision disturbances, loss of consciousness, tremor, feeling of intoxication, tinnitus, dysarthria). Rare (≥1/10,000, <1/1,000) Neuropathy, peripheral nerve damage, arachnoiditis, paresis, paraplegia Eye disorders Rare (≥1/10,000, <1/1,000) Double vision Cardiac Common (≥1/100, <1/10) Bradycardia disorders Rare (≥1/10,000, <1/1,000) Cardiac arrest, cardiac arrhythmias Vascular Very common (≥1/10) Hypotension disorders Common (≥1/100, <1/10) Hypertension Respiratory, Rare (≥1/10,000, <1/1,000) Respiratory depression thoracic and mediastinal disorders Gastrointestinal Very common (≥1/10) Nausea disorders Common (≥1/100, <1/10) Vomiting Renal and Common (≥1/100, <1/10) Urine retention urinary disorders Hepatobiliary Not known (cannot be estimated Impaired hepatic function/increase in disorders from the available data) ASAT and ALAT*. *Hepatic impairment, with reversible increases in ASAT, ALAT, ALP, and bilirubin, have been observed following repeated bupivacaine injections or bupivacaine infusions of long duration. If signs of hepatic impairment are observed during treatment with bupivacaine, the medicinal product must be discontinued immediately. (See section 4.4). Paediatric population Adverse reactions in children are similar to those in adults, but it may be difficult to detect early signs of local anaesthetic toxicity in children when blockade is given under sedation or general anaesthetic. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il. Additionally, you can also report to Padagis via the following address: Padagis.co.il.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף